In the United States, 30,000 individuals have Amyotrophic lateral sclerosis market, with 5,000 new cases diagnosed each year

 

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder. It affects the nerve cells in the central nervous system that controls the voluntary muscles. Muscle twitching, weakness, and stiff muscles are some of the symptoms of the amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis is also known as Lou Gehrig's disease.

The rising prevalence of amyotrophic lateral sclerosis is a prime factor driving growth of the amyotrophic lateral sclerosis market treatment. According to The Johns Hopkins University, it affects as many as 30,000 in the United States, with 5,000 new cases diagnosed each year. Estimates suggest that ALS is responsible for as many as five of every 100,000 deaths in people aged 20 or older. The growing geriatric population is increasing the prevalence of amyotrophic lateral sclerosis which is again propelling the growth of the amyotrophic lateral sclerosis market treatment. According to the United Nation, in 2019, there were 703 million persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050.

North America is expected to gain significant growth over the forecast period and this is attributed to increasing healthcare expenditure coupled with the high prevalence of this disorder in the region. According to the Centers for Medicare & Medicaid Services, the U.S. health care spending grew 4.6 percent in 2018, reaching $3.6 trillion or $11,172 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.

Key Developments:

In February 2020, NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug that aims to slow or halt ALS progression, announced the initiation of two clinical studies to evaluate the benefit of PrimeC for ALS patients.
In July 2020, Clinigen Group plc. the global pharmaceutical and services company, announces that the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for aldesleukin in the treatment of Amyotrophic Lateral Sclerosis (ALS).
In November 2019, Exservan™ (riluzole) Oral Film has received early-action approval from the US Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS), an orphan disease.
In January 2020, Alexion Pharmaceuticals, Inc. announced the planned initiation of a pivotal Phase 3 study of ULTOMIRIS® (ravulizumab) in amyotrophic lateral sclerosis (ALS).
In October 2020, Zhittya Genesis Medicine announces that it has been approved to initiate clinical trials in Mexico for the treatment of Amyotrophic Lateral Sclerosis (ALS)